Abstract: SA-PO0677
User Experience with Pegcetacoplan On-Body Injector in Patients with C3 Glomerulopathy or Primary Immune-Complex Membranoproliferative Glomerulonephritis
Session Information
- Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - Other
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Geara, Abdallah Sassine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Price-Schluns, Megan, Apellis Pharmaceuticals Inc, Waltham, Massachusetts, United States
- Huang, Mingyi, Apellis Pharmaceuticals Inc, Waltham, Massachusetts, United States
- Perler, Jed, Trinity Partners LLC, Waltham, Massachusetts, United States
- Hadker, Nandini, Trinity Partners LLC, Waltham, Massachusetts, United States
- Cassidy Torres, Amanda, Trinity Partners LLC, Waltham, Massachusetts, United States
- Hill, Laura, Trinity Partners LLC, Waltham, Massachusetts, United States
- Gonzalez, Nicholas, Trinity Partners LLC, Waltham, Massachusetts, United States
- Gordon, Katie, Apellis Pharmaceuticals Inc, Waltham, Massachusetts, United States
Background
Pegcetacoplan (C3/C3b inhibitor) was approved for C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) in 2025 and can be administered subcutaneously (SC); an approved on-body, single-use injector can be used for pegcetacoplan SC infusions. Here, we describe preliminary insights on satisfaction and experience with the pegcetacoplan injector for C3G and primary IC-MPGN.
Methods
This cross-sectional mixed-method (survey/interviews) study is recruiting US adult patients or caregivers of adolescent (12–17 years) patients with C3G or primary IC-MPGN who are trained for and are using the injector for ≥4 continuous weeks. After completing a web-based survey on injector use and treatment experience (7-point Likert scales), participants can take part in a 60-minute semi-structured telephone interview. Survey results are aggregated using mean ratings. Interview qualitative findings and supportive quantitative data are reported as captured for each respondent and assessed for emerging themes.
Results
This interim analysis (December 2025–April 2026) includes data from 7 patients or caregivers (mean age 37 years). Mean satisfaction with the injector was 6.7 (1-very unsatisfied, 7-very satisfied), mostly attributed to ease of setup/administration, ease of administering without help from others, and ease of injection process (mean 6.6 each [1-very difficult, 7-very easy]). Users reported that the injector is convenient to incorporate into daily life (mean 6.4 [1-do not agree, 7-strongly agree), and allows them to move freely around and perform daily activities during the injections (mean 6.0 each [1-very difficult, 7-very easy]).
Interviews from 6 patients or caregivers highlighted that the injector’s ease-of-use and portability gave users the freedom to stay active and perform their daily activities at home or away from home while managing their own treatment with confidence.
Conclusion
The majority of respondents surveyed were satisfied with multiple aspects of their experience with the pegcetacoplan injector for C3G or primary IC-MPGN.
Funding
- Commercial Support – Apellis Pharmaceuticals, Inc